Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer

This publication has 57 references indexed in Scilit:

• Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
  Cancer Research, 2014
• Engineered antibody fragments for immuno-PET imaging of endogenous CD8 ⁺ T cells in vivo
  Proceedings of the National Academy of Sciences, 2014
• Production of a PEGylated Fab′ of the anti-LINGO-1 Li33 Antibody and Assessment of Its Biochemical and Functional Properties in Vitro and in a Rat Model of Remyelination
  Bioconjugate Chemistry, 2011
• Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
  Cancer Research, 2008
• Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
  Advanced Drug Delivery Reviews, 2008
• Anti-CD30 diabody-drug conjugates with potent antitumor activity
  Molecular Cancer Therapeutics, 2008
• Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer
  Clinical Cancer Research, 2004
• Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
  Protein Engineering, Design and Selection, 2004
• Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin
  International Journal of Cancer, 2002
• Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
  Journal of Immunological Methods, 1984